[PDF] Top 20 Lenalidomide for the treatment of relapsed and refractory multiple myeloma
Has 10000 "Lenalidomide for the treatment of relapsed and refractory multiple myeloma" found on our website. Below are the top 20 most common "Lenalidomide for the treatment of relapsed and refractory multiple myeloma".
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
... that new drugs are still needed for continued disease control. Novel agents are currently being evaluated in clinical trials, and include second generation IMiDs such as pomalidomide, and second generation proteasome ... See full document
16
Efficacy of Long Term Treatment with Low Dose Thalidomide for Patients with Relapsed/Refractory Multiple Myeloma
... diagnosed multiple myeloma but also relapsed/- refractory multiple myeloma ...maintenance treatment with thalidomide upgraded the initial response status and sus- tained ... See full document
6
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
... the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome in- hibitors, histone deacetylase inhibitors and ... See full document
16
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
... Based on the available Phase I and II data, carfilzomib appears to be a safe and effective therapy for relapsed and refractory multiple myeloma. It has a favorable hematologic and renal safety ... See full document
11
Daratumumab Plus Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of POLLUX
... plus lenalidomide/dexametha- sone significantly reduced risk of progression/death versus lenalido- mide/dexamethasone alone in relapsed/refractory multiple ...plus ... See full document
9
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
... with relapsed/refractory multiple ...the treatment of the advanced and the newly diagnosed myeloma patient is currently under examination in several ongoing phase 3 clinical ... See full document
8
<p>Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective</p>
... Elotuzumab (Elo) is a humanized IgG1 mAb directed against SLAMF7, also called CS1 (cell surface glycoprotein CD2 subset 1). 12,13 SLAMF7 is a glycoprotein highly expressed on most normal and abnormal plasma cells, and ... See full document
10
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
... in 38 patients with refractory MM using PAN 20 mg dose administered three times a week given weekly in 21-day cycles. Patients had received at least two prior lines of therapy including both an IMiD (thalidomide ... See full document
11
Case Report A long-term favorable response and effective control of neutropenia obtained by low-dose pomalidomide treatment in a patient with relapsed refractory multiple myeloma: a case report
... of melphalan and prednisolone (MP) therapy was initiated after the patient was diagnosed with progressive disease (PD) in January 2015. The serum IgG level decreased from 2153 mg/dL to 1552 mg/dL; however, there was also ... See full document
9
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review
... Abstract: Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of malignant plasma cells in the bone marrow and the production of monoclonal ...(thalidomide, lenalidomide, ... See full document
7
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
... previous treatment with ...of treatment. Nineteen of 24 patients continued on treatment beyond 4 weeks to disease progression or develop- ment of a serious adverse ... See full document
8
<p>Carfilzomib for relapsed and refractory multiple myeloma</p>
... safe treatment option in patients with renal impairment, patients with liver impairment, and patients with ...frontline treatment and the sequence of (combination) treat- ment schedules in relapsed ... See full document
13
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
... cycle was established as the optimal dosing regimen. Among 22 evaluable patients with MM, 36% achieved either com- plete remission (CR) or near CR, and another 36% achieved partial remission (PR). Prior to study ... See full document
10
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
... of lenalidomide for relapsed, refractory MM has been ...oral lenalidomide for 21 days of every 28-day ...to lenalidomide alone was 25%; 24% for 30 mg once-daily and 29% for 15 mg ... See full document
8
Evaluation of noncytotoxic DNMT1 depleting therapy in patients with myelodysplastic syndromes
... 22). Treatment was well tolerated, without need for antiemetics, including in elderly subjects with organ ...with relapsed or refractory disease following first-line 5-azacytidine and/or ... See full document
14
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
... of lenalidomide at 25 mg until C4 and further lowering the doses of lenalidomide after stem cell harvesting may decrease the incidence of hematological toxicities associated with this ...Importantly, ... See full document
20
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
... Abstract: Multiple myeloma is a very heterogeneous disease with variable ...with relapsed and refractory disease have a poor ...the relapsed/ refractory ...in relapsed and ... See full document
10
Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma
... in treatment of MM based on its antiangiogenic activity and clinical activity in refractory or relapsed myeloma ...[7]. Lenalidomide (LND) is a potent novel thalidomide analog which ... See full document
9
Novel agents in the treatment of multiple myeloma: a review about the future
... the treatment of symptomatic MM, particularly with the advent of proteasome inhibitors (such as bortezomib) and immunomodulatory agents (such as lenalidomide), which have become the pillars of frontline ... See full document
20
Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
... Abstract: Treatment options for patients with multiple myeloma (MM) have increased during the past ...target relapsed or refractory multiple myeloma (RRMM) in order to ... See full document
8
Related subjects